BioMarin Pharmaceutical Inc. (BM8.DE)
EUR 61.96
(-1.71%)
EUR 61.96
(-1.71%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.41 Billion USD | 15.42% |
| 2022 | 2.09 Billion USD | 13.53% |
| 2021 | 1.84 Billion USD | -0.76% |
| 2020 | 1.86 Billion USD | 9.18% |
| 2019 | 1.7 Billion USD | 14.27% |
| 2018 | 1.49 Billion USD | 13.52% |
| 2017 | 1.31 Billion USD | 17.62% |
| 2016 | 1.11 Billion USD | 25.5% |
| 2015 | 889.89 Million USD | 18.49% |
| 2014 | 751.04 Million USD | 36.93% |
| 2013 | 548.48 Million USD | 9.54% |
| 2012 | 500.72 Million USD | 13.45% |
| 2011 | 441.35 Million USD | 17.3% |
| 2010 | 376.26 Million USD | 15.9% |
| 2009 | 324.65 Million USD | 9.5% |
| 2008 | 296.49 Million USD | 143.86% |
| 2007 | 121.58 Million USD | 44.38% |
| 2006 | 84.2 Million USD | 228.06% |
| 2005 | 25.66 Million USD | 37.7% |
| 2004 | 18.64 Million USD | 54.06% |
| 2003 | 12.1 Million USD | -13.07% |
| 2002 | 13.91 Million USD | 18.98% |
| 2001 | 11.69 Million USD | -5.09% |
| 2000 | 12.32 Million USD | 76.69% |
| 1999 | 6.97 Million USD | 481.33% |
| 1998 | 1.2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 648.83 Million USD | 0.41% |
| 2023 Q1 | 596.41 Million USD | 10.95% |
| 2023 FY | 2.41 Billion USD | 15.42% |
| 2023 Q3 | 581.32 Million USD | -2.34% |
| 2023 Q4 | 646.2 Million USD | 11.16% |
| 2023 Q2 | 595.27 Million USD | -0.19% |
| 2022 Q4 | 537.53 Million USD | 6.37% |
| 2022 Q3 | 505.34 Million USD | -5.33% |
| 2022 Q1 | 519.35 Million USD | 15.46% |
| 2022 Q2 | 533.79 Million USD | 2.78% |
| 2022 FY | 2.09 Billion USD | 13.53% |
| 2021 Q3 | 408.74 Million USD | -18.53% |
| 2021 Q4 | 449.81 Million USD | 10.05% |
| 2021 FY | 1.84 Billion USD | -0.76% |
| 2021 Q1 | 486.03 Million USD | 7.5% |
| 2021 Q2 | 501.69 Million USD | 3.22% |
| 2020 FY | 1.86 Billion USD | 9.18% |
| 2020 Q3 | 476.78 Million USD | 11.01% |
| 2020 Q1 | 502.06 Million USD | 10.48% |
| 2020 Q2 | 429.48 Million USD | -14.46% |
| 2020 Q4 | 452.11 Million USD | -5.17% |
| 2019 Q2 | 387.76 Million USD | -3.24% |
| 2019 FY | 1.7 Billion USD | 14.27% |
| 2019 Q1 | 400.74 Million USD | 13.46% |
| 2019 Q4 | 454.44 Million USD | -1.44% |
| 2019 Q3 | 461.09 Million USD | 18.91% |
| 2018 Q2 | 372.84 Million USD | -0.16% |
| 2018 FY | 1.49 Billion USD | 13.52% |
| 2018 Q1 | 373.44 Million USD | 4.23% |
| 2018 Q3 | 391.7 Million USD | 5.06% |
| 2018 Q4 | 353.21 Million USD | -9.83% |
| 2017 Q2 | 317.44 Million USD | 4.51% |
| 2017 Q3 | 334.14 Million USD | 5.26% |
| 2017 FY | 1.31 Billion USD | 17.62% |
| 2017 Q1 | 303.74 Million USD | 1.22% |
| 2017 Q4 | 358.3 Million USD | 7.23% |
| 2016 Q4 | 300.09 Million USD | 7.22% |
| 2016 Q2 | 300.13 Million USD | 26.78% |
| 2016 Q1 | 236.73 Million USD | 3.86% |
| 2016 FY | 1.11 Billion USD | 25.5% |
| 2016 Q3 | 279.89 Million USD | -6.74% |
| 2015 FY | 889.89 Million USD | 18.49% |
| 2015 Q1 | 203.26 Million USD | -11.95% |
| 2015 Q4 | 227.93 Million USD | 9.11% |
| 2015 Q3 | 208.9 Million USD | -16.61% |
| 2015 Q2 | 250.52 Million USD | 23.25% |
| 2014 Q1 | 151.55 Million USD | 3.19% |
| 2014 Q4 | 230.85 Million USD | 30.54% |
| 2014 FY | 751.04 Million USD | 36.93% |
| 2014 Q3 | 176.84 Million USD | -7.79% |
| 2014 Q2 | 191.78 Million USD | 26.55% |
| 2013 Q2 | 136.81 Million USD | 6.94% |
| 2013 Q1 | 127.92 Million USD | -3.04% |
| 2013 Q3 | 136.87 Million USD | 0.05% |
| 2013 Q4 | 146.87 Million USD | 7.31% |
| 2013 FY | 548.48 Million USD | 9.54% |
| 2012 FY | 500.72 Million USD | 13.45% |
| 2012 Q4 | 131.93 Million USD | 2.98% |
| 2012 Q1 | 116.64 Million USD | 8.16% |
| 2012 Q2 | 124.01 Million USD | 6.32% |
| 2012 Q3 | 128.11 Million USD | 3.3% |
| 2011 Q2 | 110.63 Million USD | 1.07% |
| 2011 Q4 | 107.84 Million USD | -4.92% |
| 2011 FY | 441.35 Million USD | 17.3% |
| 2011 Q3 | 113.42 Million USD | 2.53% |
| 2011 Q1 | 109.45 Million USD | 7.72% |
| 2010 Q1 | 84.95 Million USD | -2.44% |
| 2010 Q2 | 91.95 Million USD | 8.24% |
| 2010 Q3 | 97.75 Million USD | 6.31% |
| 2010 Q4 | 101.61 Million USD | 3.95% |
| 2010 FY | 376.26 Million USD | 15.9% |
| 2009 Q4 | 87.08 Million USD | 7.77% |
| 2009 Q3 | 80.8 Million USD | -2.39% |
| 2009 FY | 324.65 Million USD | 9.5% |
| 2009 Q1 | 73.98 Million USD | -25.48% |
| 2009 Q2 | 82.78 Million USD | 11.9% |
| 2008 Q2 | 64.17 Million USD | 6.26% |
| 2008 Q4 | 99.27 Million USD | 36.66% |
| 2008 Q3 | 72.64 Million USD | 13.2% |
| 2008 Q1 | 60.39 Million USD | 34.65% |
| 2008 FY | 296.49 Million USD | 143.86% |
| 2007 Q1 | 22.83 Million USD | 3.72% |
| 2007 Q2 | 28.88 Million USD | 26.47% |
| 2007 Q4 | 44.85 Million USD | 79.37% |
| 2007 Q3 | 25 Million USD | -13.43% |
| 2007 FY | 121.58 Million USD | 44.38% |
| 2006 Q2 | 23.45 Million USD | 69.78% |
| 2006 Q3 | 24.92 Million USD | 6.3% |
| 2006 FY | 84.2 Million USD | 228.06% |
| 2006 Q4 | 22.01 Million USD | -11.67% |
| 2006 Q1 | 13.81 Million USD | 45.77% |
| 2005 Q2 | 3.62 Million USD | -27.32% |
| 2005 Q1 | 4.98 Million USD | -64.1% |
| 2005 Q3 | 7.57 Million USD | 109.02% |
| 2005 Q4 | 9.47 Million USD | 25.02% |
| 2005 FY | 25.66 Million USD | 37.7% |
| 2004 Q3 | 181 Thousand USD | -96.03% |
| 2004 Q2 | 4.56 Million USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | 18.64 Million USD | 54.06% |
| 2004 Q4 | 13.89 Million USD | 7577.9% |
| 2003 FY | 12.1 Million USD | -13.07% |
| 2003 Q1 | 3.49 Million USD | 11.52% |
| 2003 Q2 | 12.1 Million USD | 246.11% |
| 2003 Q3 | - USD | -100.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q3 | 3.56 Million USD | 4.27% |
| 2002 Q4 | 3.13 Million USD | -12.16% |
| 2002 FY | 13.91 Million USD | 18.98% |
| 2002 Q1 | 3.79 Million USD | 325.59% |
| 2002 Q2 | 3.42 Million USD | -9.73% |
| 2001 Q3 | 3.74 Million USD | 2.18% |
| 2001 Q1 | 3.4 Million USD | 8.35% |
| 2001 Q4 | 891 Thousand USD | -76.2% |
| 2001 Q2 | 3.66 Million USD | 7.76% |
| 2001 FY | 11.69 Million USD | -5.09% |
| 2000 Q4 | 3.13 Million USD | 11.79% |
| 2000 FY | 12.32 Million USD | 76.69% |
| 2000 Q3 | 2.8 Million USD | -8.95% |
| 2000 Q1 | 3.29 Million USD | 44.9% |
| 2000 Q2 | 3.08 Million USD | -6.52% |
| 1999 Q2 | 1.6 Million USD | -30.43% |
| 1999 Q3 | 2 Million USD | 25.0% |
| 1999 Q4 | 2.27 Million USD | 13.8% |
| 1999 FY | 6.97 Million USD | 481.33% |
| 1999 Q1 | 2.3 Million USD | 0.0% |
| 1998 FY | 1.2 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 36.653% |
| CureVac N.V. | 53.75 Million EUR | -4400.216% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | -253.378% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | -253.378% |
| BRAIN Biotech AG | 55.33 Million EUR | -4271.963% |
| Formycon AG | 77.69 Million EUR | -3013.707% |
| Heidelberg Pharma AG | 9.85 Million EUR | -24438.468% |
| Medigene AG | 6.03 Million EUR | -39993.238% |